Artificial cornea implant aims to reverse blindness in 54-Patient trial
NCT ID NCT07526389
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This clinical trial tests a new artificial cornea (aspheric keratoprosthesis) in 54 adults with severe corneal blindness who cannot have a standard cornea transplant. Participants are randomly assigned to receive either the new device or a control device. The main goal is to see if the implant can restore enough sight to allow independent daily living within 6 months. The study is not yet recruiting and takes place at multiple sites in China.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- artificial cornea implant (aspheric keratoprosthesis)
- What this could lead to
- If successful, this could provide a new option to restore vision in people with severe corneal blindness who cannot have a standard cornea transplant.
- What could go wrong
- This is an early-stage trial with only 54 people, so results may not apply to everyone. The implant carries surgical risks like infection or device failure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORNEAL BLINDNESS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••